RA Cap­i­tal leads $125M for Janux in VC's lat­est crossover bid

Four months ago, on­ly a short list of peo­ple had ever heard of Janux Ther­a­peu­tics. To­day, they have a part­ner­ship with Mer­ck, $212 mil­lion in VC cap­i­tal and, it seems, plans for an IPO.

Janux an­nounced Tues­day a $125 mil­lion crossover round led by RA Cap­i­tal, the Boston VC be­hind a spate of re­cent pre-IPO fi­nanc­ings. Janux de­clined an in­ter­view re­quest, a com­mon move for biotechs prepar­ing to go pub­lic in the near fu­ture.

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER